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Abstract
Background: No known studies have been undertaken in South Africa exploring the contraceptive and fertility needs
and preferences of women of reproductive age (18–49) diagnosed with breast cancer. This study set out to understand
the contraceptive needs and fertility intentions of women with breast cancer in Cape Town, South Africa.
Methods: Qualitative in-depth interviews were conducted with 24 women diagnosed with breast cancer and 4 health
care providers at a tertiary hospital in Cape Town, South Africa. We explored contraceptive use prior to diagnosis; the
impact of breast cancer on future fertility intentions and contraceptive use; understanding of suitable contraceptive
methods during and after treatment and women’s fertility related counseling needs during their continuum of care.
Data were analysed using a thematic analysis approach.
Results: Since being diagnosed with breast cancer, of those women using a contraceptive method, the non-hormonal
intrauterine device (IUD) was the most commonly used method. However, women reported receiving limited
information from health care providers about contraceptive use and future fertility planning post treatment when
fertility desires might change. Many women reported limited information received from healthcare providers about the
impact of cancer treatment on their future fertility. Most women did not receive information around fertility
preservation options, and few were familiar with the concept. Providers focus was more on preventing pregnancy
during treatment and ensuring a patient was on a non-hormonal contraceptive method. Providers supported a more
holistic, multidisciplinary approach to breast cancer patient’s contraceptive and future fertility needs.
Conclusions: Limited contraceptive and future fertility counseling were reported by women despite many women
being provided with the IUD. There is a need for improved information and counseling regarding the impact of
treatment on contraceptive and fertility options. It is important that cancer care providers provide timely information
regarding fertility options and communicate with patients about their fertility concerns prior to treatment and
throughout the course of survivorship. The development of evidence-based information tools to enhance patient-
provider communication and counseling could address knowledge gaps.
Keywords: Breast cancer, Contraception, Fertility intentions, Fertility preservation, South Africa, Qualitative methods
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Jane.Harries@uct.ac.za
1Women’s Health Research Unit, School of Public Health and Family
Medicine, University of Cape Town, Cape Town, South Africa
Full list of author information is available at the end of the article
Harries et al. BMC Women's Health          (2020) 20:224 
https://doi.org/10.1186/s12905-020-01094-3
Background
Breast cancer remains the commonest cancer among
women globally with about 2.1 million newly diagnosed
female breast cancer cases in 2018 [1]. In South Africa,
breast cancer is the commonest form of cancer among
women, with an age-standardised incidence rate of 35.95
per 100,000 women and a major cause of cancer mortal-
ity [2]. South Africa does not have a national mammog-
raphy screening programme. Typically, women with
breast symptoms self-present to primary healthcare facil-
ities and are referred to secondary or tertiary level health
facilities for further investigation, treatment and care [3].
Breast cancer is an important women’s health issue, and
premenopausal women with breast cancer comprise a special
subgroup with unique concerns regarding contraception,
early menopause, infertility, and future fertility options [4–7].
Despite women’s need for information on these issues their
levels of knowledge are considered lacking compounded by
limited fertility and contraceptive counseling available to
women, especially younger women [4, 7–10].
Contraception is challenging for women with cancer,
particularly those with breast cancer, who are limited to
long-acting non-hormonal methods, the copper T380A
intrauterine device (IUD), as hormonal contraception is
contraindicated and discontinued in women with breast
cancer [10–13]. Contraceptive counseling in breast can-
cer patients is complex and involves different decisions
and choices during the continuum of care including
contraceptive counseling at diagnosis, preventing preg-
nancy during treatment, contraceptive counseling post
treatment and avoiding hormonal contraceptives [8, 14].
Pregnancy during breast cancer treatment is contraindi-
cated as chemotherapy administered during the first tri-
mester results in increased congenital malformations
[12, 13, 15]. Most clinicians recommend a delay of at
least 2 years after treatment, to allow aggressive breast
cancer to become manifest before considering preg-
nancy, underlining the need for effective, long- acting
non-hormonal contraceptive methods [12, 15].
Although breast cancer treatment, especially chemo-
therapy and hormonal therapy, may have detrimental ef-
fects on ovarian function, it does not preclude the
possibility of pregnancy during treatment and under-
scores the need for contraceptive counseling and adher-
ence to avoid an unintended pregnancy [8, 15]. The
impact of chemotherapy on fertility is significant. Coun-
seling regarding the possibility of fertility preservation
with either ovary or zygote preservation before treat-
ment is important [16]. However, the desire to preserve
fertility needs to be balanced against the urgency of can-
cer treatment as ovarian stimulation will often require a
month or two of delay in the starting of systemic treat-
ment [16]. These delays may be significant in poorer
resourced health settings where services are not
necessarily available in the public sector, and when they
are available, waiting times are often long, making fertil-
ity preservation options unavailable to many women.
When a woman is diagnosed with breast cancer, initial
consultations with the multidisciplinary oncology team
focuses predominantly on issues such as the implication
of the cancer diagnosis itself, multimodal cancer therapy
and coping with a life-threatening disease leaving little
room and time for contraceptive counseling [7, 10].
Most oncologists are not experienced in the field of
contraception and refer most patients to gynaecologists
or family planning clinics [10, 17]. Little is known what
happens once women are referred for contraceptive
counseling or whether they receive the most suitable
contraceptive method or continue with the method.
There is limited data on the contraceptive and fertility
counseling needs for women with breast cancer in high-
and middle-income countries and no studies in Sub Sa-
haran Africa, including South Africa [4, 8]. This study
set out to explore the contraceptive needs and fertility
intentions of women of reproductive age (18–49) under-
going breast cancer treatment with the view to support
contraceptive and fertility counseling along the con-
tinuum of breast cancer care from diagnosis and treat-
ment to survivorship. Health care providers views and
experiences of breast cancer patient’s contraceptive and
fertility needs were explored to provide further insight
into provider-patient counseling needs.
Methods
Qualitative research methods were used to collect data.
In-depth interviews were conducted with women under-
going breast cancer treatment, and health care providers
from the Breast Clinic at a large public sector tertiary
hospital in Cape Town, South Africa. The population
typically served by this large teaching hospital are
poorer, under-served patients most of whom do not
have private medical insurance. The hospital is also the
main referral centre in the Cape Town metropole for
women with breast cancer symptoms. The hospital pro-
vides breast cancer services to approximately 2.5 million
people in the Cape Town area.
The Breast Clinic is an open access, one-stop diagnos-
tic clinic where women may present with a letter from a
primary level provider (nurse practitioner or doctor).
The breast clinic provides clinical and cytological evalu-
ation with direct referral to an oncologist if breast cy-
tology is positive for malignancy. Newly diagnosed
patients are reviewed by a multidisciplinary team includ-
ing breast surgeons, nurses, oncologists, radiologists, pa-
thologists and social workers. Treatment options include
chemotherapy, radiation, breast surgery and genetic
counseling. Family planning services are available at the
hospital.
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Recruitment and study population
Breast cancer patients
Study participants were selected through purposive sam-
pling. In-depth interviews were conducted with 24
women between 2017 and 2018 undergoing different
stages of breast cancer treatment. Twenty-nine eligible
women were recruited, four did not arrive for their
scheduled interview and one woman did not want to
wait. Women were recruited with the assistance of the
breast clinic staff who helped identify women who were
of reproductive age (18–49), diagnosed with breast can-
cer in the past 5 years and willing to be interviewed
about their reproductive and fertility choices. Contracep-
tive use was not an eligibility criteria. We chose a five-
year window to limit recall bias. All women were attend-
ing an outpatient appointment at the breast clinic for
follow up visits and some were receiving chemotherapy
treatment. Eligible participants were identified by the
clinic nurse, the research assistant then approached the
study participant and further explained the study and in-
vited women to participate in the study.
Providers
Prior to the commencement of the study, the first author
(JH) met with two clinicians and a genetic counsellor in-
volved in breast cancer treatment and care who then
suggested suitable providers to approach. Four in-depth
interviews were conducted with health care providers
working within the breast clinic and involved in different
aspects of treatment and care and included a breast sur-
geon, oncologist, nursing coordinator and palliative care
physician. Interviews were conducted in 2019.
Data collection
Semi-structured interviews were conducted by female re-
search assistants trained in qualitative research methods
in a private space within the hospital. All interviews were
audio recorded and conducted in English, isiXhosa or Af-
rikaans and transcribed and translated into English by an
independent transcriber. Interviews were 45–60min in
duration. Data saturation was achieved.
Key areas explored amongst breast cancer patients in-
cluded; responses to breast cancer diagnosis and what
this might mean for future fertility intentions, under-
standings of suitable contraceptive methods during and
after treatment, and future fertility options including fer-
tility preservation. Key areas explored amongst providers
included views and opinions around contraceptive and
fertility options for women with breast cancer including
counseling and intervention needs. Interviewers kept
fieldnotes which provided added context when reviewing
the transcripts. The interview guides were piloted, and
changes were made to improve flow and clarity (see
Additional files 1 and 2).
Data analysis
Data were analysed using a thematic analysis approach,
in which main themes and categories were identified
and analysed within and across data. Initial categories
for analysing data were drawn from the interview guide,
and then themes and patterns were identified after
reviewing the data. The qualitative software package
NVivo 12 Pro was used to facilitate sorting and data
management.
All transcripts were reviewed by the Principal Investi-
gator and first author (JH) and a preliminary list of
codes were developed. The transcripts were coded by a
member of the research team (JH) and an independent
coder and cross checked for coder variation. The data
was then reviewed for major trends, crosscutting themes,
and issues for further exploration.
Ethical considerations
Ethical approval was obtained from the Human Research
Ethics Committee, University of Cape Town. Permission
to conduct the study was obtained from the tertiary hos-
pital. All study participants provided written informed
consent prior to the interview process. Verbal permis-
sion was obtained from all study participants prior to
digitally recording interviews. Confidentiality and ano-
nymity were ensured. All data were closely controlled
and stored in locked files and password protected com-
puter files. Digital recordings were erased once they had
been cross checked after data transcription. All women
were reimbursed ZAR 100 for their time. Providers were
not reimbursed. Study participants had access to coun-
seling services should they require assistance.
Results
Participant characteristics
The median age for women (n = 24) was 36.5 years, 54%
were married or in a long-term relationship, 50% un-
employed and 46% had completed high school. Seventy
five percent of women (18/24) reported using a contra-
ceptive method, of these 18 women half (9/18) were
using the copper T380A IUD, other methods included
sterilisation and condoms. More than half of the women
(62%) at the time of the interview did not plan to have
more children. No women at the time of the interview
were known to be pregnant.
Five broad themes were identified linked to the contra-
ceptive and fertility counseling pathways during breast
cancer treatment and recovery. These included; i)
contraceptive use pre diagnosis; ii) contraception and
counseling needs during treatment iii) future fertility in-
tentions iv) fertility preservation options and v) optimal
time for contraceptive and fertility counseling.
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Contraceptive use pre diagnosis
We explored patients contraceptive use pre diagnosis as
this might have influenced future contraceptive use es-
pecially if women were required to change their current
contraceptive method. Prior to their breast cancer diag-
nosis, some women discussed having received limited in-
formation about contraceptive method choices from
healthcare providers. A breast cancer patient explained:
Nobody … gave me any advice on contraception they
[healthcare providers] just said that you have to take a
contraceptive and you have to use that one [3 monthly
injectable]. [Age range 41–45, 3 children].
Similarly, another patient recalled limited postpartum
contraceptive counseling and method choice which in-
fluenced subsequent contraceptive uptake.
When my daughter was born, they [nurses] told me
you must go on something before you leave the hospital.
So, it wasn’t my choice, they decided for me. So, I went
with the injection it was not a good choice. I didn’t know
all the pros and cons … I really didn’t want to because I
mean why would I want to put something in me that I
don’t know what is going inside of me. [Age range 30–35,
2 children].
Contraception and counseling during treatment
At diagnosis and during treatment most women reported
limited fertility and contraceptive counseling apart from in-
formation around changing current hormonal contraception
to a non-hormonal method (IUD); the importance of avoid-
ing pregnancy during treatment, and the possible impact of
their cancer treatment on future fertility.
Contraception (non-hormonal methods)
Contraceptive counseling tended to focus on ensuring that
patients who were using hormonal methods (injectable and
subdermal implant) were provided with the copper T380A
IUD prior to treatment highlighted in the excerpts below:
I was on the 3 months injection [DMPA] … they
stopped that and then I had to change to the loop [IUD]
… it prevents the hormones from developing … I can’t use
the injection now because of the cancer. [Age range 46–
49, 4 children].
The doctor [oncologist] did discuss contraception be-
cause when I was having my next visit for Petogen
[DMPA] … I was already diagnosed with breast cancer
… the doctor said I must stop it because it’s not good for
me … they gave me a pamphlet to read at home, they
did tell me everything about the IUD. [Age range 36–40,
2 children].
However, contraceptive counseling and provision at
diagnosis and during treatment was not consistent
and some women were concerned about the associ-
ated risks of an unintended pregnancy. A patient re-
ported receiving limited contraceptive counseling
prior to treatment and was concerned about contra-
ceptive safety while undergoing treatment.
No, I didn’t get advice about family planning … I
would have liked to know if I need a family planning, is
it safe for me? … I didn’t think about the family planning
yet. But I’m going to ask if it’s safe for me to use it. [Age
range 41–45, 1 child].
Related to possible risk, a woman who desired another
child considered her options and was fearful of the
teratogenic effects of chemotherapy on a pregnancy.
Before I got diagnosed, we were going to try again to
have another child. … But then the doctor also told me
that if I fall pregnant while on treatment, they will stop
the treatment and obviously I want to have the baby … if
I get pregnant even when I’m on treatment it can be that
maybe my child can die inside of me if I didn’t know I
am pregnant, that’s why you have to be on the loop
[IUD] or a condom. [Age range 36–40, 2 children].
Contraception and counseling: providers
Whilst providers recognised the importance of contra-
ceptive counseling, they noted that their focus as clini-
cians was on pregnancy prevention during treatment
rather than on providing comprehensive contraceptive
and fertility counseling during a patient’s treatment
trajectory.
A provider concurred with women’s accounts around
inconsistent reproductive health counseling, which
sometimes resulted in an unintended pregnancy.
There is a discussion about not falling pregnant with
patients, but obviously then things fall through the cracks
… it depends on how it goes on the day, who sees you,
whether it’s brought up or not. Sometimes this has conse-
quences – we have had a few cases of patients who fell
pregnant in between treatments.
Oncologists main concern was on pregnancy preven-
tion as chemotherapy (especially tamoxifen) was contra-
indicated in pregnancy. A provider explained that the
focus tended to be on preventing a pregnancy during
chemotherapy and less on future fertility intentions.
But fertility is not brought into it so much, it is being
mentioned that for the period of your chemotherapy, do
not fall pregnant. Not taking it any further than fertili-
ty...do you want to have more children in the future, do
we have facilities to do banking … that’s not part of the
discussion.
Future fertility intentions
Women’s future fertility intentions were influenced by
numerous factors including their perceived health status,
reaching their family size, partner’s desire for more chil-
dren, suitable time interval before a pregnancy and un-
derstandings around the safety of childbearing post
cancer treatment.
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However, whilst many women did receive information
about avoiding pregnancy during treatment and the need
to change to a non- hormonal contraceptive method,
most women did not receive adequate information on
future fertility possibilities or a suitable time in their
treatment trajectory to consider childbearing.
An older married woman reflected on her continued
desire to have children and sought medical confirmation
as to a suitable time to have another child.
I want to get information [about childbearing] from the
doctor again because I want to know now after I’m fin-
ished with the chemo and I want to find out if I’m
healthy now to have more children. My hopes were al-
ways to have another child … Before I found out I had
cancer … my husband and I were planning to get preg-
nant, but I must first hear what the doctor says. [Age
range 41–45, 3 children].
Health was an overriding concern and informed deci-
sions about future childbearing.
I am going to have more children when I see that I am
well and when I see that my health has completely im-
proved then I will resume with having children. [Age
range 25–29, 1 child].
However, many women did not want more children
having reached their family size or were faced with the
reality of a cancer diagnosis and were unsure of their fu-
ture wellbeing.
No, I do not want any more children I already have
my blessings. [Age range 36–40, 4 children].
A woman explained that despite wanting another child
she and her partner had come to accept that childbear-
ing was not possible due to her breast cancer diagnosis.
When I mentioned it [fertility options] to him [part-
ner]... He was also very shocked and disappointed] … we
didn’t get that chance to discuss it because I just got sick
and went for tests and then it’s the cancer … so we didn’t
really have that chance to sit and talk with each other
about having another baby … I would have loved an-
other one, but unfortunately, I can’t … so for me I’ve got
my pigeon pair already, the boy and a girl so for me it’s
fine. [Age range 36–40, 2 children].
Fertility preservation
We explored whether patients had received any informa-
tion about fertility preservation procedures prior to
treatment. Most patients had not received any informa-
tion about fertility preservation options, and few were fa-
miliar with the concept.
Almost all woman had “never heard about fertility
preservation”. However, a woman who desired more
children explained how she sought information on the
internet.
No they did not discuss fertility options I actually goo-
gled it … apparently you can have kids after you had all
this radiation and chemo … I actually read up about
that [fertility preservation] … and then I thought to my-
self wasn’t I supposed to do that? [Age range 36–40, 2
children and would like 2 more children].
Fertility preservation: providers
Providers concurred that fertility preservation options
were not discussed and highlighted the difficulties of dis-
cussing fertility preservation as it was not easily available
in the public sector. Despite there being limited fertility
preservation options, especially for younger women, on-
cologists suggested the possibility of treatment with the
gonadotropin-releasing hormone (GnRH) agonist to re-
duce the risk of chemotherapy induced premature ovar-
ian insufficiency, but cost was an inhibiting factor.
One of the resources that would help is to have access
to ovarian preservation, like your GnRH agonist and then
we can give that to younger childbearing women … but
there would have to be some sort of subsidy because of
the cost.
Optimal time for contraceptive and fertility counseling
Providers explored the optimal time in a patient’s treat-
ment trajectory where contraceptive and fertility coun-
seling should occur, suggesting that sexual and
reproductive health (SRH) counseling should be inte-
grated into treatment and care. All providers stressed
the importance of a “holistic and multidisciplinary” ap-
proach to contraceptive and fertility counseling.
I think contraceptive and fertility counseling needs to
be along the continuum of care. I think it’s something
that needs to be brought up again and again … and part
of a multidisciplinary medical team.
Whilst women did not directly discuss their sexual
health needs, some providers noted that contraceptive
and fertility counseling needed to include broader SRH
discussions including altered body image and impact of
treatment on femininity and motherhood.
It’s also very important that a person understands that
when you do get breast cancer and you’ve gone through
all this stuff, your role as a woman has changed … your
femininity … So there’s the sense of I am still a woman, I
can still have children, I haven’t changed. I think that
sense of who I am as a woman needs to be very clearly
discussed with patients, now that they have gone through
this kind of treatment.
A health care provider noted that contraception needs
to be part of a broader conversation around sexuality
and recognised the difficulties as they were not trained
in having conversations about more intimate issues.
It’s not just a conversation about contraception it’s a
wider conversation ... it’s sexuality as well … I don’t think
you can only just look at contraception. It is the easy,
tangible thing, … sexuality is much more complex to deal
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with … and I don’t think we have trained our health care
providers enough in having a sexuality conversation.
A nurse provider who was involved in counseling pa-
tients prior to treatment explained that they did not dis-
cuss family planning or contraception in depth nor was
it included in the information booklet provided to breast
cancer patients.
The information booklet that I give women with breast
cancer doesn’t include contraception and family planning
just sexual dysfunction.
Discussion
This is the first study undertaken in South Africa explor-
ing the contraceptive and fertility needs and preferences
of women diagnosed with breast cancer. Contraceptive
counseling focused on discontinuation of hormonal
methods and encouraged the uptake of the non-
hormonal IUD. Whilst 50% of the women using contra-
ception reported receiving the IUD prior to commence-
ment of treatment, it is unclear whether they continued
with their method once treatment was complete.
Unintended pregnancies with the possibility of foetal
abnormalities due to adjuvant therapy were reported by
providers and underscores the importance of compre-
hensive contraceptive counseling before and during
treatment. In our study women were diagnosed and
treated within a relatively short time period, yet women
were still at risk of unintended pregnancy and the asso-
ciated health risks of carrying a pregnancy to term.
Our study is not too dissimilar to research in other
countries with more well-resourced oncology services
where contraceptive counseling is more likely to occur
at diagnosis rather than during treatment and survivor-
ship [4, 10, 11, 18]. However, our study was somewhat
different as contraceptive uptake post diagnosis was rela-
tively high amongst study participants compared to
other studies in high income settings [4, 7, 19]. The rela-
tively high uptake of the IUD post diagnosis might be
different for other non-hormonally mediated cancers
and is not reflective of overall IUD uptake in South Af-
rica where the IUD remains under-utilized [20, 21].
Both breast cancer patients and providers reported
limited contraceptive counseling throughout the course
of treatment highlighting the need for improved infor-
mation and counseling regarding the impact of treat-
ment on contraceptive and fertility options especially for
younger patients desiring more children. Furthermore,
clinicians treating women with breast cancer did not
feel they had the requisite skills in providing compre-
hensive contraceptive and fertility counseling.
Infertility after treatment is a major concern for young
women with breast cancer particularly as it relates to op-
portunities for future childbearing [5, 6, 14]. Research in
developed country contexts with more comprehensive
programs have highlighted breast cancer patients con-
cerns that their fertility options including fertility preser-
vation were not adequately addressed, exacerbated by a
paucity of available information [19, 22, 23]. Providers
and patients in our study concurred with these senti-
ments. Providers felt constrained in discussing fertility
preservation options as they were not available or feas-
ible in terms of cost. Fertility preservation options for
younger women with breast cancer are complex and re-
quires a multidisciplinary approach including oncologists
and reproductive specialists. While there are some well-
established options for fertility preservation for women
who can afford the cost, many options remain experi-
mental and uncertain [12, 16].
Optimal timing of contraceptive and fertility counsel-
ing is important not only in preventing a pregnancy and
the associated health consequences but also in providing
patients with future fertility options, recognising the per-
sonal and emotional experiences of a breast cancer diag-
nosis. Research has suggested numerous factors are at
play at the time of diagnosis, during treatment and into
survivorship which could impact on fertility related deci-
sion making [4–6, 17]. The timing of counseling played
a role in our study and women were not always sure of
the best option in terms of future fertility intentions.
While not explicitly stated, study participants might have
also prioritized survivorship over long-term fertility in-
tentions [4, 17].
Clear guidelines for oncological teams around the need
for content, timing and frequency of SRH information
has been identified as an often-overlooked area espe-
cially for younger breast cancer patients [18, 19]. Associ-
ated with the development of these guidelines should be
regular SRH educational workshops for multidisciplinary
oncology teams to facilitate appropriate counseling to
patients. This will facilitate a timely referral pathway be-
tween the oncology team to a reproductive health spe-
cialist that could provide specialist knowledge, such as
fertility preservation options, to assist patients in making
informed decisions [8, 10, 11, 16].
An additional area that could be explored in SRH edu-
cational workshops includes management of breast can-
cer diagnosed during pregnancy or treatment.
Limitations
This study has limitations. While the provider sample
was small it assisted in triangulating the data and com-
plemented the findings. Breast cancer patients in this
study were all seen at a large oncology department
within a major teaching hospital, and the findings may
not be generalizable to other parts of the country, espe-
cially rural areas where access to health services, includ-
ing cancer care services, might be more challenging.
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Conclusions
Women undergoing breast cancer treatment did not consist-
ently receive counseling on contraception or future fertility
options as a part of their care despite being provided with
the non- hormonal IUD prior to treatment.
There is a need for improved information and counsel-
ing regarding the impact of treatment on contraceptive
and feasible fertility options. It is important that health
care providers provide timely and ongoing information
regarding fertility options and communicate with breast
cancer patients about their fertility concerns prior to
treatment and throughout the treatment trajectory in-
cluding survivorship. The development of evidence-
based information tools via print and social media plat-
forms could facilitate patient-provider communication
and address knowledge gaps especially for younger pa-
tients desiring more children. Information tools could
also facilitate discussion between not only providers and
patients but also wider social networks including family,
friends, partners and support groups.
While it is recognized that oncology teams in South
Africa are over stretched providing the essentials of can-
cer care, raising awareness and knowledge about the
SRH needs of women with breast cancer amongst all
team members, patients and social networks, will
catalyze an improvement in contraceptive and fertility
support for women during their cancer journey.
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